Abstract
Spotlight commentary: Navigating between financial risks and improved treatment outcomes with immune checkpoint inhibitors in cancer patients: The need for biomarker identification and dose optimization.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have